Royalty Pharma Plc (RPRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $39.85B
Last updated: Nov 17, 2026 at 11:06 AM ET
Royalty Pharma Plc (RPRX) Stock Forecast
Analysts expect Royalty Pharma Plc (RPRX) to earn $5.39 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.52B. Of 8 analysts, 7 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $5.91.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 88% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 25.0% |
| Buy | 5 | 62.5% |
| Hold | 1 | 12.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 9.6% and revenue estimates rise 9.9%.
- Fiscal year ending Dec 31, 2026
- $5.39
- EPS consensus, revenue $3.52B
- Fiscal year ending Dec 31, 2027
- $5.91
- EPS consensus, revenue $3.87B
- Next report
- Feb 9, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $5.39 | $5.31 to $5.49 | 6 | $3.52B | $3.42B to $3.58B | 5 |
| Dec 31, 2027 | $5.91 | $5.59 to $6.23 | 6 | $3.87B | $3.81B to $3.97B | 4 |
Quarterly Estimates
The EPS consensus falls from $1.56 for the quarter ending Dec 31, 2026 to $1.45 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.56 | $1.36 to $1.72 | 9 | $836.33M | $546.68M to $1.03B | 8 |
| Mar 31, 2027 | $1.45 | $1.30 to $1.59 | 2 | N/A | N/A | 0 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 4 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.5% from $5.31.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $5.39 | $5.32 | $5.34 | $5.33 | $5.31 | +1.5% |
| Fiscal year ending Dec 31, 2027 | $5.91 | $5.81 | $5.73 | $5.74 | $5.68 | +4.0% |
| Quarter ending Mar 31, 2027 | $1.45 | $1.30 | $1.29 | $1.25 | $1.25 | +15.6% |
Frequently Asked Questions About RPRX
What is the RPRX stock forecast?
Consensus analyst estimates put Royalty Pharma Plc's EPS at $5.39 for the fiscal year ending Dec 31, 2026, on revenue of $3.52B. The consensus rating from 8 analysts is Buy.
How do analysts rate RPRX stock?
Of 8 analysts covering Royalty Pharma Plc, 2 rate it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RPRX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $5.39, with estimates from $5.31 to $5.49 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $5.91, with estimates from $5.59 to $6.23 from 6 analysts.
What revenue do analysts expect from Royalty Pharma Plc next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.52B, with estimates from $3.42B to $3.58B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.87B, with estimates from $3.81B to $3.97B.
How many analysts cover RPRX?
8 analysts rate Royalty Pharma Plc stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RPRX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors